Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

DOI: https://doi.org/10.3233/BLC-219500

2021-03-19

Bladder Cancer

Abstract:[This corrects the article DOI: 10.3233/BLC-200013.].

What problem does this paper attempt to address?

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Jiaojiao Hao,Zhenglin Li,Changlin Zhang,Wendan Yu,Zhipeng Tang,Yixin Li,Xu Feng,Yue Gao,Quentin Liu,Wenlin Huang,Wei Guo,Wuguo Deng

DOI: https://doi.org/10.62347/suki5933

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 13 in vol. 7, PMID: 28123844.].
Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

DOI: https://doi.org/10.1177/17588359241290373

2024-10-21

Abstract:[This corrects the article DOI: 10.1177/17588359241267148.].
Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Frontiers Production Office

DOI: https://doi.org/10.3389/fphar.2022.1092147

IF: 5.6

2022-11-22

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.973448.].

pharmacology & pharmacy
Erratum to “Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis”

Chenglin Han,Zilong Wang,Shuxiao Chen,Lin Li,Yingkun Xu,Weiting Kang,Chunxiao Wei,Hongbin Ma,Muwen Wang,Xunbo Jin

DOI: https://doi.org/10.1155/2021/9857803

2021-12-14

Oxidative Medicine and Cellular Longevity

Abstract:[This corrects the article DOI: 10.1155/2021/8851763.].

cell biology
Erratum: Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946

DOI: https://doi.org/10.1182/bloodadvances.2017011148

2017-08-17

Abstract:[This corrects the article DOI: 10.1182/bloodadvances.2016004176.].
Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Zhilin Li,Hao Cai,Zhiqian Li,Long Ren,Xuelei Ma,Hongyan Zhu,Qiyong Gong,Hu Zhang,Zhongwei Gu,Kui Luo

DOI: https://doi.org/10.1016/j.bioactmat.2022.09.016

IF: 18.9

2023-04-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.08.028.].

engineering, biomedical,materials science, biomaterials
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Hongzhi Li,Weihua Yuan,Shufang Bin,Guang Wu,Panyuan Li,Min Liu,Jifeng Yang,Xiang Li,Kaiyan Yang,Haihua Gu

2022-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 688 in vol. 10, PMID: 32195036.].
Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

DOI: https://doi.org/10.1182/blood-2016-06-725010

IF: 20.3

2016-08-18

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2015-04-639203.].
Correction To: Predictive Biomarkers and Mechanisms Underlying Resistance to PD1/PD-L1 Blockade Cancer Immunotherapy.

Daixi Ren,Yuze Hua,Boyao Yu,Xin Ye,Ziheng He,Chunwei Li,Jie Wang,Yongzhen Mo,Xiaoxu Wei,Yunhua Chen,Yujuan Zhou,Qianjin Liao,Hui Wang,Bo Xiang,Ming Zhou,Xiaoling Li,Guiyuan Li,Yong Li,Zhaoyang Zeng,Wei Xiong

DOI: https://doi.org/10.1186/s12943-020-01148-y

IF: 37.3

2020-01-01

Molecular Cancer

Abstract:After publication of the article [1], authors found out that Fig. 1 was inadvertently replaced.
Erratum: Author correction to '3- O-Acetyl-11-keto- β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma' [Acta Pharm Sin B 10 (2020) 301-312]

Wan Li,Liwen Ren,Xiangjin Zheng,Jinyi Liu,Jinhua Wang,Tengfei Ji,Guanhua Du

DOI: https://doi.org/10.1016/j.apsb.2024.04.025

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2019.12.012.].
Erratum: A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro: Erratum.

Jianfa Li,ChenChen Huang,Tiefu Xiong,Changshui Zhuang,Chengle Zhuang,Yawen Li,Jing Ye,Yaoting Gui

DOI: https://doi.org/10.7150/ijbs.91212

2024-01-01

International Journal of Biological Sciences

Abstract:[This corrects the article DOI: 10.7150/ijbs.32332.].
Erratum: Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy: Erratum

DOI: https://doi.org/10.1097/JD9.0000000000000184

Abstract:[This corrects the article DOI: 10.1097/JD9.0000000000000170.].
Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Thomas Morgan Hulen,Christina Friese,Nikolaj Pagh Kristensen,Joachim Stoltenborg Granhøj,Troels Holz Borch,Marlies J W Peeters,Marco Donia,Mads Hald Andersen,Sine Reker Hadrup,Inge Marie Svane,Özcan Met

DOI: https://doi.org/10.3389/fimmu.2024.1462081

2024-07-18

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1180997.].
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang,Bo-Ya Xiao,Peng-Cheng Li,Bo-Hua Kuang,Wang-Bing Chen,Pin-Dong Li,Guo-He Lin,Quentin Liu

DOI: https://doi.org/10.1155/2021/3735726

IF: 4.501

2021-02-25

Journal of Oncology

Abstract:[This corrects the article DOI: 10.1155/2020/2368164.].

oncology
Erratum: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2024.1516456

IF: 4.7

2024-11-06

Frontiers in Oncology

Abstract:This article is an erratum on: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

oncology
Erratum: Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2023.1281693

2023-09-27

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1169537.].
Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

DOI: https://doi.org/10.1182/blood-2016-06-723056

IF: 20.3

2016-07-28

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2008-10-184143.].
Erratum: Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074

DOI: https://doi.org/10.1182/blood-2016-07-727081

IF: 20.3

2016-08-18

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2014-12-615187.].
Erratum: Kini Bailur J, Mehta S, Zhang L, et al. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv. 2017;1(25):2343-2347

DOI: https://doi.org/10.1182/bloodadvances.2017015438

2018-01-09

Abstract:[This corrects the article DOI: 10.1182/bloodadvances.2017012732.].

Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Erratum to “Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis”

Erratum: Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

Correction To: Predictive Biomarkers and Mechanisms Underlying Resistance to PD1/PD-L1 Blockade Cancer Immunotherapy.

Erratum: Author correction to '3- O-Acetyl-11-keto- β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma' [Acta Pharm Sin B 10 (2020) 301-312]

Erratum: A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro: Erratum.

Erratum: Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy: Erratum

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Erratum: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

Erratum: Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

Erratum: Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074

Erratum: Kini Bailur J, Mehta S, Zhang L, et al. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv. 2017;1(25):2343-2347